Drug Profile
Lamotrigine chewable dispersible tablet
Alternative Names: Lamotrigine CD; Lamictal CDT; Lamotrigine CD tablet; Lamotrigine chewable tablet; Lamotrigine dispersible tabletLatest Information Update: 16 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antidepressants; Antiepileptic drugs; Chlorobenzenes; Mood stabilisers; Small molecules; Triazines
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bipolar disorders; Epilepsy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Epilepsy in China (PO, Fast dissolve)
- 01 Dec 2015 GlaxoSmithKline completes a phase III trial in Bipolar disorders in China (NCT01602510)
- 01 Nov 2015 GlaxoSmithKline completes a phase I trial In volunteers in China (PO) (NCT02513654)